<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02831491</url>
  </required_header>
  <id_info>
    <org_study_id>16404</org_study_id>
    <secondary_id>I4T-MC-JVDN</secondary_id>
    <secondary_id>2016-001317-25</secondary_id>
    <nct_id>NCT02831491</nct_id>
  </id_info>
  <brief_title>A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Single-Arm, Phase 2 Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to evaluate the safety of the study drug ramucirumab in&#xD;
      combination with weekly docetaxel in participants with stage IV non-small cell lung cancer&#xD;
      (NSCLC) following disease progression after prior platinum-based chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    To pursue broader program objectives in oncology.&#xD;
  </why_stopped>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">January 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants with Grade ≥3 Neutropenia</measure>
    <time_frame>Baseline through End of Study (Approximately 20 Months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Febrile Neutropenia</measure>
    <time_frame>Baseline through End of Study (Approximately 20 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR): Percentage of Participants With a Complete or Partial Response</measure>
    <time_frame>Baseline to Objective Progression or Start of New Anti-Cancer Therapy (Approximately 20 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>Baseline to Objective Progression or Death from Any Cause (Approximately 20 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Baseline to Date of Death Due to Any Cause (Approximately 20 Months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Minimum Concentration (Cmin) of Ramucirumab</measure>
    <time_frame>Baseline through End of Study (Approximately 20 Months)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Stage IV Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Ramucirumab + Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramucirumab given intravenously (IV) on day 1 every 3 weeks followed by weekly IV infusion of docetaxel on days 1, 8, and 15 every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Ramucirumab + Docetaxel</arm_group_label>
    <other_name>LY3009806</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Ramucirumab + Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The participant had disease progression on or after prior platinum-based chemotherapy&#xD;
             regimen for locally advanced or metastatic NSCLC.&#xD;
&#xD;
          -  Prior immunotherapy for NSCLC is allowed.&#xD;
&#xD;
          -  The participant has an Eastern Cooperative Oncology Group performance status of 0 or&#xD;
             1.&#xD;
&#xD;
          -  The participant has histologically or cytologically confirmed NSCLC.&#xD;
&#xD;
          -  The participant has metastatic NSCLC disease (Stage IV) at the time of first dose of&#xD;
             study treatment.&#xD;
&#xD;
          -  The participant has measurable disease at the time of first dose of study treatment&#xD;
             documented by computed tomography (CT) scan or magnetic resonance imaging (MRI).&#xD;
&#xD;
          -  The participant has resolution to Grade ≤1 by the National Cancer Institute-common&#xD;
             terminology criteria for adverse events (NCI-CTCAE), Version 4.0, of all clinically&#xD;
             significant toxic effects of prior locoregional therapy, surgery, or other anticancer&#xD;
             therapy.&#xD;
&#xD;
          -  The participant has adequate organ function.&#xD;
&#xD;
          -  The participant's urine protein is &lt;2+ on dipstick or routine urinalysis (UA). If&#xD;
             urine dipstick or routine analysis indicates proteinuria ≥2+, then a 24-hour urine&#xD;
             must be collected and must demonstrate &lt;2 grams of protein in 24 hours to allow&#xD;
             participation in the study.&#xD;
&#xD;
          -  For male participants, are sterile (including vasectomy confirmed by post vasectomy&#xD;
             semen analysis) or agree to use a highly effective method of contraception (2 methods&#xD;
             preferred, or per country requirements, whichever is more strict), and to not donate&#xD;
             sperm starting with the first dose of study treatment, during the study, and for at&#xD;
             least 6 months following the last dose of study treatment or country requirements,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  For female participants, are surgically sterile, postmenopausal, or agree to use a&#xD;
             highly effective method of contraception (2 methods preferred, or per country&#xD;
             requirements, whichever is more strict) during the study and for 6 months following&#xD;
             the last dose of study treatment or country requirements, whichever is longer.&#xD;
&#xD;
          -  Female participants of childbearing potential must have a negative serum or urine&#xD;
             pregnancy test within 72 hours prior to first dose of study treatment.&#xD;
&#xD;
          -  The participant has a life expectancy of ≥3 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with docetaxel or ramucirumab.&#xD;
&#xD;
          -  The participant has received more than 1 prior chemotherapy regimen for locally&#xD;
             advanced or metastatic NSCLC; however, prior maintenance chemotherapy for locally&#xD;
             advanced or metastatic NSCLC is allowed.&#xD;
&#xD;
          -  The participant's tumour contains small cell lung cancer.&#xD;
&#xD;
          -  The participant has undergone major surgery within 28 days prior to first dose of&#xD;
             study treatment, or subcutaneous venous access device placement within 7 days prior to&#xD;
             first dose of study treatment. Furthermore, any participant with postoperative&#xD;
             bleeding complications or wound complications from a surgical procedure performed in&#xD;
             the last 2 months will be excluded.&#xD;
&#xD;
          -  The participant has a bowel obstruction, history or presence of inflammatory&#xD;
             enteropathy or extensive intestinal resection (hemicolectomy or extensive small&#xD;
             intestine resection with chronic diarrhea), Crohn's disease, ulcerative colitis, or&#xD;
             chronic diarrhea.&#xD;
&#xD;
          -  The participant has peripheral neuropathy Grade ≥2 (NCI-CTCAE v 4.0).&#xD;
&#xD;
          -  The participant has an elective or a planned major surgery during the course of the&#xD;
             trial.&#xD;
&#xD;
          -  The participant is receiving concurrent treatment with other anticancer therapy,&#xD;
             including other chemotherapy, immunotherapy, hormonal therapy, chemoembolization, or&#xD;
             targeted therapy.&#xD;
&#xD;
          -  The participant has symptomatic, active, or untreated central nervous system (CNS)&#xD;
             metastases. Brain metastases that are asymptomatic, stable and not requiring steroid&#xD;
             use, and previously treated by radiation are allowed. The participant may have no&#xD;
             evidence of Grade ≥1 CNS hemorrhage based on pretreatment MRI or I.V. contrast CT scan&#xD;
             (performed within 21 days before first dose of study treatment).&#xD;
&#xD;
          -  The participant has radiologically documented evidence of major blood vessel invasion&#xD;
             or encasement by cancer.&#xD;
&#xD;
          -  The participant has radiographic evidence of intratumor cavitation, regardless of&#xD;
             tumor histology.&#xD;
&#xD;
          -  The participant has a history of uncontrolled hereditary or acquired thrombotic&#xD;
             disorder.&#xD;
&#xD;
          -  The participant is receiving chronic therapy with nonsteroidal anti-inflammatory drugs&#xD;
             (NSAIDs; for example, indomethacin, ibuprofen, naproxen, or similar agents) or other&#xD;
             antiplatelet agents (for example, clopidogrel, ticlopidine, dipyridamole, and&#xD;
             anagrelide). Aspirin (acetylsalicylic acid) use at doses up to 325 milligrams/day is&#xD;
             permitted.&#xD;
&#xD;
          -  Participants with a history of gross hemoptysis (defined as bright red blood or ≥1/2&#xD;
             teaspoon) within 2 months prior to first dose of study treatment.&#xD;
&#xD;
          -  The participant has clinically relevant congestive heart failure (New York Heart&#xD;
             Association Class II-IV) or symptomatic or poorly controlled cardiac arrhythmia.&#xD;
&#xD;
          -  The participant has experienced any arterial thrombotic event, including myocardial&#xD;
             infarction, unstable angina, cerebrovascular accident, or transient ischemic attack,&#xD;
             within 6 months prior to first dose of study treatment.&#xD;
&#xD;
          -  The participant has uncontrolled arterial hypertension ≥150 / ≥90 millimeters of&#xD;
             mercury despite standard medical management.&#xD;
&#xD;
          -  The participant has had a serious or nonhealing wound, ulcer, or bone fracture ≤28&#xD;
             days prior to first dose of study treatment.&#xD;
&#xD;
          -  The participant has significant bleeding disorders, vasculitis, or experienced Grade&#xD;
             3-4 gastrointestinal (GI) bleeding within 3 months prior to first dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  History of GI perforation and / or fistulae within 6 months prior to first dose of&#xD;
             study treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>https://www.lillytrialguide.com/en-US/studies/advanced-cancer/JVDN#?postal=</url>
    <description>A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>July 11, 2016</study_first_submitted>
  <study_first_submitted_qc>July 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2016</study_first_posted>
  <last_update_submitted>June 8, 2020</last_update_submitted>
  <last_update_submitted_qc>June 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.&#xD;
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

